Target CXCR4Class Cyclic peptide
Structure from the cited PubChem record (unlabelled ligand, or the labelled form when PubChem only describes that one). Conformer: RDKit (computed conformer, indicative). Rotate with the mouse or a finger.
| Form | Use | Molar mass (labelled form) | Ongoing trials | Most advanced phase | Approval |
|---|---|---|---|---|---|
| [⁶⁸Ga]Ga-pentixafor Syntheses and QC ↗ | Imaging | — | 18 | Phase 3 | — |
| [¹⁷⁷Lu]Lu-pentixather Syntheses and QC ↗ | Therapy | — | 1 | Phase 2 | — |
| [⁹⁰Y]Y-pentixather Syntheses and QC ↗ | Therapy | — | 1 | Phase 2 | — |
Atlas trials whose studied drug or title names this vector, with this radionuclide.
| Trial | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
| [68Ga]pentixafor2024-512628-12-00 · Adrenal | Phase 3 | Recruiting | Stichting Radboud universitair medisch centrum | 1 |
| PentiMyelo · [68Ga]pentixaforNCT04561492 · Myeloma | Phase 2 | Active, not recruiting | Nantes University Hospital | 1 |
| [68Ga]pentixaforNCT06246357 · Adrenal | Phase 2 | Recruiting | National Cancer Institute (NCI) | 1 |
| [68Ga]pentixafor2022-501811-14-00 · Myeloma | Phase 2 | Recruiting | University Of Antwerp | 2 |
| [68Ga]pentixaforNCT07350707 · Adrenal | Phase 2 | Recruiting | Peking Union Medical College Hospital | 1 |
| [177Lu/90Y]PentixatherNCT06132737 · Brain (glioma, medulloblastoma…) | Phase 2 | Recruiting | Pentixapharm AG | 1 |
| [68Ga]pentixafor2025-523646-27-00 · Heart failure and cardiomyopathies | Phase 2 | Not yet recruiting | Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) | 1 |
| PENTALON · [68Ga]pentixaforNCT06478875 · Adrenal | Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 1 |
| PentixaFor · [68Ga]pentixaforNCT06461182 · Lymphoma | Phase 2 | Recruiting | Koo Foundation Sun Yat-Sen Cancer Center | 1 |
| PENTILULA · [177Lu/90Y]PentixatherNCT06356922 · Leukemia / transplant conditioning | Phase 2 | Active, not recruiting | Nantes University Hospital | 1 |
| [68Ga]pentixaforNCT04504526 · Lymphoma | Phase 1 | Recruiting | First Affiliated Hospital of Fujian Medical University | 1 |
| [68Ga]pentixaforNCT03335670 · NETs and neuroendocrine carcinomas (other) | Phase 1 | Active, not recruiting | Yusuf Menda | 1 |
| [68Ga]pentixaforNCT05093335 · Lymphoma | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 1 |
| PASSIFLORE · [68Ga]pentixaforNCT07007325 · Small-cell lung cancer | Phase 1 | Not yet recruiting | Institut Cancerologie de l'Ouest | 1 |
| [68Ga]pentixaforNCT07577206 · Myeloma | Phase 1 | Recruiting | National Cancer Institute, Naples | 1 |
| [68Ga]pentixaforNCT06833437 · Adrenal | No phase | Recruiting | Qifu Li | 1 |
| [68Ga]pentixaforNCT05255926 · Solid tumors (multiple indications) | No phase | Recruiting | Zhongnan Hospital | 1 |
| [68Ga]pentixaforNCT06871176 · Myeloma | No phase | Recruiting | University Health Network, Toronto | 1 |
| [68Ga]pentixaforNCT05188872 · Adrenal | No phase | Recruiting | First Affiliated Hospital of Fujian Medical University | 1 |
| EXIGENCE · [68Ga]pentixaforNCT06962163 · Breast | No phase | Recruiting | Institut Cancerologie de l'Ouest | 1 |
| 2026-06 | PentixaFor in marginal zone lymphoma · positiveIn 41 untreated patients, PentixaFor detects far more disease sites than FDG (lymph nodes 97% vs 40%, stomach 72% vs 40%). It changes the stage in 29% of patients and management in 56%. | Eur J Nucl Med Mol Imaging ↗ |
384 publications in PubMed for the query below; the most recent:
pentixafor[tiab] OR pentixather[tiab]
Sources: PubChem and PubMed (NCBI), ClinicalTrials.gov and CTIS registries, approvals recorded by the atlas. PubChem data as of 28 October 2026.
Pentixafor / pentixather. Theranostic Atlas, LaRadiopharmacie.fr. Data as of 27 October 2026. https://theranosticatlas.com/molecule/pentixafor/ (accessed [date]).
A monitoring tool with no regulatory value: check every item at its source.